An old drug with a new future: Bendamustine in multiple myeloma

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2263-2280

  Gentile, Massimo ^a   Recchia, Anna Grazia ^a   Mazzone, Carla ^a   Vigna, Ernesto ^a   Martino, Massimo ^b   Morabito, Lucio ^c   Lucia, Eugenio ^a   Bossio, Sabrina ^a   De Stefano, Laura ^a   Granata, Teresa ^a   Palummo, Angela ^a   Morabito, Fortunato ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

ASCT; Bendamustine; Multiple myeloma; New drugs; Therapy

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ETOPOSIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; I KAPPA B; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; PROTEIN KINASE B INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; SILTUXIMAB; THALIDOMIDE; VORINOSTAT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BREAST CANCER; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MITOSIS INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PLASMA CELL LEUKEMIA; PROGRESSION FREE SURVIVAL; RASH; REFRACTORY PERIOD; RELAPSE; RISK ASSESSMENT; SARCOMA; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ALKYLATING AGENTS; HUMANS; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 84885643412     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.837885     Document Type: Article

References (133)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33 (Pubitemid 36033957)
3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
4. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-17
5. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418-22
6. Blade J, Rosinol L, Cibeira MT. Are all myelomas preceded by MGUS Blood 2009;113:5370
7. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011;183:25-35
8. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
9. Gentile M, Recchia AG, Mazzone C, et al. Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther 2013;13(Suppl 1):S1-S22
10. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9 (Pubitemid 46972782)
11. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6
12. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
13. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011;17(6):1253-63
14. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 2010;376:2075-85
15. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41
16. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011;16:1600-3
17. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-57
18. Blade J, Dimopoulos M, Rosinol L, et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010;28:690-7
19. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582-90 (Pubitemid 46961003)
20. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7
21. Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438-47
22. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114:5436-43
23. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 2004;104:3052-7 (Pubitemid 39507119)
24. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18 (Pubitemid 47516593)
25. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy withautologous stem cell transplantation. Leukemia 2009;23:1716-30
26. Chanan-Khan AA, Lonial S, Weber D, et al. Lenalidomide in combination with dexamethasone improves survival and time-to progression in patients 65 years old with relapsed or refractory multiple myeloma. Int J Hematol 2012;96:254-62
27. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80
28. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-3
29. Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375-82
30. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800-7
31. Attal M, Lauwers V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-91
32. Mellqvist UH, Westin J, Gimsing P, et al. Improved response rate with bortezomib consolidation after high dose melphalan: first results of a Nordic Myeloma Study Group randomized phase III trial. Blood (ASH annual meeting abstracts) 2009;114:221
33. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010;28:2077-84
34. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-94
35. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stemcell transplantation procedure. J Clin Oncol 2009;27:1788-93
36. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113-20
37. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012. [Epub ahead of print]
38. Morgan GJ, Davies FE, Gregory WM, et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood (ASH annual meeting abstracts) 2009;114:149
39. Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial. Blood (ASH annual meeting abstracts) 2010;116:23
40. Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008;113:355-9
41. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30 (Pubitemid 43357806)
42. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010;28:1209-14
43. Offidani M, Corvatta L, Polloni C, et al. Thalidomide-dexamethasone versus interferon-alpha dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Haematol 2009;144:653-9
44. Attal M, Lauwers V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-91
45. Mc Carthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81
46. Palumbo A, Adam Z, Kropff M, et al. A phase 3 study evaluating the efficacy and safety of lenalidomide (Len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (Pts) 65 years (Yrs) with newly diagnosed multiple myeloma (NDMM): updated results for pts aged 65-75 yrs enrolled in MM-015. Blood (ASH Annual Meeting Abstracts) 2011;118:475
47. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMGHD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood (ASH annual meeting abstracts) 2010;116:23
48. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidationmaintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800-7
49. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-86
50. Siegel DS, Jacobus S, Rajkumar SV, et al. Outcome with lenalidomide plusdexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial. Blood (ASH Annual Meeting Abstracts) 2010;116:38
51. Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012;118:1585-92
52. Palumbo A, Cavallo F, Hardan I, et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients 65 years: results of a randomized phase III study. Blood (ASH annual meeting abstracts) 2011;118:3069
53. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (IFM/DFCI2009). Available from: http://www. clinicaltrials.gov/ct2/show/NCT01208662 term-nct01208662&rank-1 [Accessed 12 December 2011]
54. Study to compare VMP with HDM followed by VRD consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (HO95). Available from: http://www. clinicaltrials.gov/ct2/show/NCT01208766 [Accessed 12 December 2011]
55. A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects. Available from: http://clinicaltrials.gov/show/ NCT01091831
56. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502 (Pubitemid 38010075)
57. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol 2007;25:2434-41 (Pubitemid 46999214)
58. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010;28:1209-14
59. Ludwig H, Beksac M, Blade J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010;15:6-25
60. Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623-8
61. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4
62. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095-110
63. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278-88
64. San Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008;26:2761-6
65. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85 (Pubitemid 46978271)
66. van Rhee F, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010;116:1220-7
67. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010;115:4168-73
68. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009;146:164-70
69. Stewart AK, Chang H, Trudel S, et al. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia 2007;21:2358-9 (Pubitemid 350011711)
70. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005;44:194-203 (Pubitemid 41306648)
71. Chng WJ, Ketterling RP, Fonseca R. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer 2006;45:1111-20 (Pubitemid 44763439)
72. Ozegowski W, Krebs D. IMET3393 ([1methyl-5-bis-(b-chloroethyl)- aminobenz-imidazolyl-(2)]-butyric acid hydrochloride, a new cytotoxic agent from among the series of benzimidazole mustard compounds [in German]. Zbl Pharm 1971;110:1013-19
73. Anger G, Hesse P, Baufeld H. Treatment of multiple myeloma with a new cytostatic agent: gamma-1-methyl-5-bis- (b-chloroethyl)-amino-benzimidazalyl- (2)]-butyric acid hydrochloride. Dtsch Med Wochenschr 1969;94:2495-500
74. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972;287:386-9
75. Heider A, Kress M, Niederle N. Bendamustine as second line therapy in patients with relapsed lowgrade non- Hodgkin's lymphoma and multiple myeloma [in German]. Tumor Diagn Ther 1997;18:71-5 (Pubitemid 27331813)
76. Schmittel A, Knoedler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small-cell lung cancer patients. Lung Cancer 2007;55:109-13 (Pubitemid 46043579)
77. Loibl S, Murmann C, Schwedler K, et al. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: riTa trial. Cancer Chemother Pharmacol 2009;63:953-8
78. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 2012;30(Suppl):abstract 3
79. Zaborowska A, Cebula B, Franiak Pietryga I, et al. The influence of bendamustine used either alone or in combination with purine nucleoside analogues on the viability and apoptosis of chronic lymphocytic leukemia cells in culture in vitro. Acta Haematol Pol 2009;40:887-98
80. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory and alkylator refractory, indolent, and transformed non-Hodgkin's lymphoma: results of a phase II multicenter single agent study. J Clin Oncol 2008;26:204-10
81. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-64 (Pubitemid 41503651)
82. Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007;110:861-6 (Pubitemid 47257665)
83. Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Health Syst Pharm 2010;67:713-23
84. Knauf WU, Lissichkov T, Aldaound A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84
85. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-9
86. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab refractory, indolent B-cell non-Hodgkin lymphoma. Cancer 2010;116:106-14
87. Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab refractor indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:452-7
88. Ogura M, Uchida M, Taniwaki M, et al. Phase I and pharmacokinetic study of bendamustine in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2054-8
89. Gandhi V. Metabolism and mechanism of action of bendamustine: rationales for combination therapy. Semin Oncol 2002;29(Suppl 13):4-11 (Pubitemid 34857890)
90. Herold M, Keinert K, Anger G, et al. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease results of a pilot study. Oncology 1992;15:502-5 (Pubitemid 23080543)
91. Leoni LM, Baliey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanism features compared with other alkylating agent. Clin Cancer Res 2008;14:309-17 (Pubitemid 351378007)
92. Roue G, Lopez-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14:6907-15
93. Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413-23
94. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating, cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972;287:386-9
95. Haase D, Preiss R, Sohr R. Untersuchungen zur Plasmaeiweissbindung von Bendamustine (Cytostasan) und Ambazon. Z Klein Med 1990;45:1267-72 (Pubitemid 20276741)
96. Preiss R, Sohr R, Matthias M, et al. The pharmacokinetics of bendamustine (Cytostasan) in humans. Pharmazie 1985;40:782-4
97. Chovan JP, Li F, Yu E, Ring SC. Metabolic profile of [(14)C] bendamustine in rat urine and bile: preliminary structural identification of metabolites. Drug Metab Dispos 2007;35:1744-55
98. Ujjani CH, Cheson BD. Bandamustine in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2010;10:1353-6534
99. Teichert J, Sohr R, Hennong L, et al. Identification and quantitation of the Nacetyl- L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. Drug Metab Dispos 2009;37:292-301
100. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007;59:759-70 (Pubitemid 46440598)
101. Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of alkylatorbendamustine and their identification in human bile, urine and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005;33:984-92 (Pubitemid 41002781)
102. Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure response relationship in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010;66:1039-49
103. Leoni LM. Bendamustine: rescue of effective antineoplastic agent from the mid-twentieth century. Semin Oncol 2011;48(Suppl 1):4-11
104. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-8 (Pubitemid 41375295)
105. Michael M, Bruns I, Bolke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13-19
106. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012;53:632-4
107. Hrusovsky I, Heidtmann HH. Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma. Clinical observation. Blood (ASH Annual Meeting Abstracts) 2007;110:4851
108. Fenk R, Michael M, Zohren F, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007;48:2345-51 (Pubitemid 350253466)
109. Ludwig H, Kasparu H, Greil R, et al. Treatment with bendamustine- bortezomib-dexamethasone (BBD) in relapsed/refractory multiple myeloma shows significant activity and is well tolerated. Blood (ASH Annual Meeting Abstracts) 2012;120:943
110. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160:321-30
111. Ponisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2012;139:499-508
112. Rodon P, Hulin C, Pegourie B, et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly patients with multiple myeloma in first relapse: updated results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 trial. Blood (ASH Annual Meeting Abstracts) 2012;120:4044
113. Rodon P, Hulin C, Pegourie B, et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly MM progressive after 1st line therapy (IFM 2009-01 Trial): predictive factors of defavourable outcome. Haematologica 2013;98(Suppl 1):231
114. Ponisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol 2008;143:191-200
115. Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012;156:552-5
116. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of a phase 1-2 open-label dose escalation study. Blood 2012;119:4608-13
117. Ponisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol 2013;162:202-9
118. Sacchi S, Pozzi S, Badiali S, et al. A phase I/II study of bendamustine, low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2012;120:1851
119. Kumar SK, Krishnan A, Roy V, et al. Phase I/II, multicenter, open-label, dose-escalation study of bendamustine in combination with lenalidomide and dexamethasone (BRD) in patients with relapsed multiple myeloma: a multiple myeloma research consortium study. Blood (ASH Annual Meeting Abstracts) 2012;120:2965
120. Musto P, Fraticelli VL, Mansueto G, et al. Bendamustine as salvage therapy in multiple myeloma: a retrospective, multicenter study from the Italian compassionate use program in 78 heavily pre-treated patients. Blood (ASH Annual Meeting Abstracts) 2012;120:2971
121. Aguado Bueno B, Andres IV, Entrena L, et al. Preliminary experience of the Spanish compassionate use registry of bendamustine in patients with relapsed and/or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2012;120:4035
122. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and Prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-12 (Pubitemid 43144255)
123. Berdeja JG, Savona MR, Essell J, et al. Bendamustine, bortezomib anddexamethasone (BBD) as first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules. Blood (ASH Annual Meeting Abstracts) 2012;120:4047
124. Ponisch W, Wiesler J, Leiblein S, et al. Successful mobilization of peripheral blood stem cells after intensive bendamustine pre-treatment in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2010;116:4439
125. Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013;19:831-7
126. Preiss R, Teichert J, Ponisch W, et al. Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease. Hematol J 2003;4(Suppl 1):263
127. Ponisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 2012;138:1405-12
128. Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011;155:632-4
129. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2009;28:4976-84
130. Ludwig H, Rauch E, Zdenek A, et al. Toxicity profile during treatment with bendamustine bortezomibdexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 2013;98(Suppl 1):807
131. Pratt G, Bowcock S, Lai M, et al. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. Int J Lab Hematol 2013; Epub ahead of print
132. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-501
133. Blumel S, Goodrich A, Martin Ch, Dang NH. Bendamustine: a novel cytotoxic agent for hematological malignancies. Clin J Oncol Nurs 2008;12:799-806